List – 51 Drug Patents that are Expiring in 2023
In 2020, we published an article covering 91 drug patents expiring between 2020-2022. 2022 is already here and if you are working in the pharma domain, working on the development of generics, you would want to know what drug patents are expiring in the coming years, so you could plan accordingly.
With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible, and keeping that very thought in mind, we collated a list of 51 drugs that are going off-patent 2023. We also included other information like yearly sales, dosage information, ingredients, and the diseases they cure. This could help you easily choose the drug most profitable to develop a generic version.
Loved the idea and the list? Thank us later in the comments section. Now onto the list.
The article has a list of drug patents expiring in 2023. If you want to get the drug patents expiration list from 2021 to 2025, Download the PDF by filling out the form below.
Drug Patents Expiring in 2023
Entresto
Sacubitril; Valsartan
Sacubitril; Valsartan
Sales:
$1.7 Billion (2018)
$1.7 Billion (2018)
| Patents | Expiration Date |
|---|---|
| US8404744 | July 14, 2023 |
| US8796331 | July 14, 2023 |
| US7468390 | November 27, 2023 |
| US8101659 | January 15, 2025 |
Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corporation
Ingredients: Sacubitril; Valsartan
Treatment: Chronic Heart Failure
Spinraza
Nusinersen Sodiumz
Nusinersen Sodiumz
Sales:
$1.724 Billion (2018)
$1.724 Billion (2018)
| Patents | Expiration Date |
|---|---|
| US7101993 | September 05, 2023 |
| US8110560 | December 05, 2025 |
| US7838657 | July 11, 2027 |
| US8361977 | May 27, 2030 |
Dosage: Solution; Intrathecal
Company: Biogen Idec Inc
Ingredients: Nusinersen Sodium
Treatment: Spinal Muscular Atrophy
Tegsedi
Inotersen Sodium
Inotersen Sodium
Sales:
$2.2 Million (Q4, 2018)
$2.2 Million (Q4, 2018)
| Patents | Expiration Date |
|---|---|
| US7015315 | March 21, 2023 |
| US7101993 | September 05, 2023 |
Dosage: Solution; Subcutaneous
Company: Akcea Therapeutics Inc
Ingredients: Inotersen Sodium
Treatment: Polyneuropathy
Dalvance
Dalbavancin Hydrochloride
Dalbavancin Hydrochloride
Sales:
$81.9 Million (2019)
$81.9 Million (2019)
| Patents | Expiration Date |
|---|---|
| US6900175 | December 25, 2023 |
| US7115564 | November 14, 2023 |
| US7119061 | November 14, 2023 |
| US8143212 | November 14, 2023 |
Dosage: Powder; Intravenous
Company: Allergan Sales LLC
Ingredients: Dalbavancin Hydrochloride
Treatment: To Treat Severe Skin Infections
Zykadia
Ceritinib
Ceritinib
Sales:
$91 Million (2016)
$91 Million (2016)
| Patents | Expiration Date |
|---|---|
| US9416112 | January 31, 2023 |
| US8188276 | January 31, 2023 |
| US9018204 | January 31, 2023 |
| US8835430 | January 31, 2023 |
| US7893074 | April 25, 2026 |
| US9018204 | November 20, 2027 |
| US7964592 | April 29, 2028 |
| US8039479 | June 29, 2030 |
| US9309229 | January 18, 2032 |
Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Ceritinib
Treatment: Lung Cancer
Promacta
Eltrombopag Olamine
Eltrombopag Olamine
Sales:
$330 Million (Q4, 2018)
$330 Million (Q4, 2018)
| Patents | Expiration Date |
|---|---|
| US7160870 | May 20, 2023 |
| US7547719 | January 13, 2026 |
Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Eltrombopag Olamine
Treatment: Thrombocytopenia
Rubraca
Rucaparib Camsylate
Rucaparib Camsylate
Sales:
$142 – $143 Million (2019)
$142 – $143 Million (2019)
| Patents | Expiration Date |
|---|---|
| US6495541 | November 22, 2023 |
| US9045487 | February 10, 2031 |
| US8754072 | February 10, 2031 |
Dosage: Tablet; Oral
Company: Clovis Oncology Inc
Ingredients: Rucaparib Camsylate
Treatment: BRCA-Mutated Ovarian Cancer
Mektovi
Binimetinib
Binimetinib
Sales:
$35.1 Million (Q3, 2019)
$35.1 Million (Q3, 2019)
| Patents | Expiration Date |
|---|---|
| US7777050 | March 13, 2023 |
| US8178693 | March 13, 2023 |
| US8193229 | March 13, 2023 |
| US8513293 | March 13, 2023 |
| US9562016 | October 18, 2033 |
Dosage: Tablet; Oral
Company: Array Biopharma Inc
Ingredients: Binimetinib
Treatment: Unresectable or Metastatic Melanoma with a BRAF V600 Mutation
Zosyn
Piperacillin Sodium, Tazobactam Sodium
Piperacillin Sodium, Tazobactam Sodium
Sales:
$51 Million (2019)
$51 Million (2019)
| Patents | Expiration Date |
|---|---|
| US6900184 | April 14, 2023 |
| US7915229 | April 14, 2023 |
| US8133883 | April 14, 2023 |
Dosage: Injectable; Injection
Company: Wyeth Pharmaceuticals LLC
Ingredients: Piperacillin Sodium; Tazobactum Sodium
Treatment: Bacterial Infections
Boniva
Ibandronate Sodium
Ibandronate Sodium
Sales:
$517 Million (2011)
$517 Million (2011)
| Patents | Expiration Date |
|---|---|
| US7192938 | May 06, 2023 |
| US7410957 | May 06, 2023 |
| US7718634 | May 06, 2023 |
Dosage: Injectable; Injection
Company: Hoffmann La Roche Inc
Ingredients: Ibandronate Sodium
Treatment: Osteoporosis
Votrient
Pazopanib Hydrochloride
Pazopanib Hydrochloride
Sales:
$828 Million (2018)
$828 Million (2018)
| Patents | Expiration Date |
|---|---|
| US7105530 | October 19, 2023 |
Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Pazopanib Hydrochloride
Treatment: Soft Tissue Sarcomas and Advanced Renal Cell Carcinoma
Tyzeka
Telbivudine
Telbivudine
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7858594 | September 11, 2023 |
| US7589079 | September 11, 2023 |
Dosage: Solution; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Telbivudine
Treatment: Chronic Hepatitis B
Exforge
Amlodipine Besylate; Hydrochlorothiazide; Valsartan
Amlodipine Besylate; Hydrochlorothiazide; Valsartan
Sales:
$1.025 Billion (2019)
$1.025 Billion (2019)
| Patents | Expiration Date |
|---|---|
| US8101599 | May 16, 2023 |
| US8475839 | May 16, 2023 |
Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Amlodipine Besylate; Hydrochlorothiazide; Valsartan
Treatment: High Blood Pressure (Hypertension)
Ozurdex
Dexamethasone
Dexamethasone
Sales:
$33.7 Million (Q3, 2019)
$33.7 Million (Q3, 2019)
| Patents | Expiration Date |
|---|---|
| US8034366 | January 09, 2023 |
| US8034370 | January 09, 2023 |
| US9192511 | January 09, 2023 |
| US10076526 | January 09, 2023 |
| US6899717 | November 01, 2023 |
| US8506987 | January 09, 2023 |
| US10702539 | January 09, 2023 |
Dosage: Implant; Intravitreal
Company: Allergan Inc
Ingredients: Dexamethasone
Treatment: Macular Edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)
Feraheme
Ferumoxytol
Ferumoxytol
Sales:
$41.7 Million (Q4, 2019)
$41.7 Million (Q4, 2019)
| Patents | Expiration Date |
|---|---|
| US6599498 | June 30, 2023 |
Dosage: Solution; Intravenous
Company: Amag Pharmaceuticals Inc
Ingredients: Ferumoxytol
Treatment: Iron Deficiency Anemia
Patanase
Olopatadine Hydrochloride
Olopatadine Hydrochloride
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7977376 | February 02, 2023 |
| US8399508 | September 17, 2022 |
Dosage: Spray, Metered; Nasal
Company: Novartis Pharmaceuticals Corp
Ingredients: Olopatadine Hydrochloride
Treatment: Congestion, Sneezing, and Runny Nose caused by Seasonal Allergies
Mozobil
Plerixafor
Plerixafor
Sales:
$108.3 Million (2018)
$108.3 Million (2018)
| Patents | Expiration Date |
|---|---|
| US6987102 | July 22, 2023 |
| US7897590 | July 22, 2023 |
Dosage: Solution; Subcutaneous
Company: Genzyme Corp
Ingredients: Plerixafor
Treatment: Non-Hodgkin’s Lymphoma or Multiple Myeloma
Oraverse
Phentolamine Mesylate
Phentolamine Mesylate
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7229630 | June 20, 2023 |
| US7569230 | October 17, 2023 |
Dosage: Injectable; Injection
Company: Septodont Holding SAS
Ingredients: Phentolamine Mesylate
Treatment: Used for Reversal of the Soft-Tissue Anesthesia
Ryzolt
Tramadol Hydrochloride
Tramadol Hydrochloride
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7988998 | October 27, 2023 |
Dosage: Tablet, Extended Release; Oral
Company: Purdue Pharma Products LP
Ingredients: Tramadol Hydrochloride
Treatment: Severe Pain
Toviaz
Fesoterodine
Fesoterodine
Sales:
$69 Million (2020)
$69 Million (2020)
| Patents | Expiration Date |
|---|---|
| US6858650 | January 3, 2023 |
Dosage: Oral
Company: Pfizer
Ingredients: FESOTERODINE FUMARATE
Treatment: Overactive Bladder Syndrome (OAB)
Ibrance
Palbociclib
Palbociclib
Sales:
$1.43 Billion (2020)
$1.43 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US6936612 | January 16, 2023 |
| US7208489 | January 16, 2023 |
| USRE47739 | March 5, 2027 |
| US10723730 | February 8, 2034 |
Dosage: Oral
Company: Pfizer
Ingredients: PALBOCICLIB
Treatment: HR-positive and HER2-negative breast cancer
Vizamyl
Flutemetamol
Flutemetamol
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7351401 | January 24, 2023 |
| US8236282 | May 21, 2024 |
| US7270800 | September 3, 2025 |
Dosage: Intravenous
Company: GE Healthcare
Ingredients: FLUTEMETAMOL F-18
Treatment: Used as a Diagnostic Tool for Alzheimer’s disease
Janumet
Sitagliptin/Metformin
Sitagliptin/Metformin
Sales:
$5.2 Billion (2020)
$5.2 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US6699871 | January 26, 2023 |
| US7326708 | May 24, 2027 |
Dosage: Oral
Company: Merck & Co
Ingredients: METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Treatment: Type 2 Diabetes
Lexapro
Escitalopram
Escitalopram
Sales:
DKK 1.83 Billion (2021)
DKK 1.83 Billion (2021)
| Patents | Expiration Date |
|---|---|
| US6916941 | February 12, 2023 |
Dosage: Oral
Company: Lundbeck
Ingredients: ESCITALOPRAM OXALATE
Treatment: Major Depressive Disorder or Generalized Anxiety Disorder
Victoza
Liraglutide
Liraglutide
Sales:
DKK 15.05 Billion (2021)
DKK 15.05 Billion (2021)
| Patents | Expiration Date |
|---|---|
| US6268343 | February 22, 2023 |
| US8114833 | February 13, 2026 |
Dosage: Subcutaneous
Company: Novo Nordisk
Ingredients: LIRAGLUTIDE RECOMBINANT
Treatment: Type 2 Diabetes, Obesity, and Chronic Weight Management
Fosamax
Alendronic Acid
Alendronic Acid
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7964212 | March 6, 2023 |
| US7488496 | August 11, 2023 |
Dosage: Oral
Company: Merck & Co Inc
Ingredients: ALENDRONATE SODIUM
Treatment: Osteoporosis and Paget’s Disease of Bone
Koselugo
Selumetinib
Selumetinib
Sales:
$108 Million (2021)
$108 Million (2021)
| Patents | Expiration Date |
|---|---|
| US8178693 | March 13, 2023 |
| US7425637 | April 11, 2024 |
| US9562017 | December 12, 2026 |
| US9156795 | December 12, 2026 |
Dosage: Oral
Company: AstraZeneca
Ingredients: SELUMETINIB SULFATE
Treatment: Neurofibromatosis type I (NF-1)
Akynzeo
Netupitant / Palonosetron
Netupitant / Palonosetron
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US6297375 | March 17, 2023 |
| US10233154 | September 25, 2035 |
| US9951016 | September 25, 2035 |
| US10961195 | September 25, 2035 |
| US10676440 | September 25, 2035 |
Dosage: Oral, Intravenous
Company: Helsinn Therapeutics
Ingredients: NETUPITANT; PALONOSETRON HYDROCHLORIDE
Treatment: Acute and Delayed Chemotherapy-induced Nausea and Vomiting
Kynamro
Mipomersen
Mipomersen
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7015315 | March 21, 2023 |
| US7511131 | January 29, 2027 |
Dosage: Subcutaneous Injection
Company: Genzyme Corporation
Ingredients: MIPOMERSEN SODIUM
Treatment: Homozygous Familial Hypercholesterolemia
Incruse Ellipta
Umeclidinium bromide
Umeclidinium bromide
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| USRE44874 | March 23, 2023 |
| US7498440 | April 27, 2025 |
| US7439393 | May 21, 2025 |
| US7488827 | December 18, 2027 |
Dosage: Inhalation
Company: GlaxoSmithKline
Ingredients: UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)
Xeljanz
Tofacitinib
Tofacitinib
Sales:
$696 Milllion (2020)
$696 Milllion (2020)
| Patents | Expiration Date |
|---|---|
| US6965027 | March 25, 2023 |
| USRE41783 | December 8, 2025 |
Dosage: Oral
Company: Pfizer
Ingredients: TOFACITINIB CITRATE
Treatment: Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis
Vocabria
Cabotegravir
Cabotegravir
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US8080551 | April 11, 2023 |
| US7125879 | April 21, 2025 |
Dosage: Oral, Intramuscular
Company: ViiV Healthcare
Ingredients: CABOTEGRAVIR; RILPIVIRINE
Treatment: HIV/AIDS
Dexilant
Dexlansoprazole
Dexlansoprazole
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US6664276 | July 30, 2023 |
Dosage: Oral
Company: Takeda
Ingredients: DEXLANSOPRAZOLE
Treatment: Gastroesophageal Reflux Disease
Dutrebis
Lamivudine/raltegravir
Lamivudine/raltegravir
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7820660 | April 25, 2023 |
Dosage: Oral
Company: Merck Sharp & Dohme Corp.
Ingredients: LAMIVUDINE; RALTEGRAVIR POTASSIUM
Treatment: HIV/AIDS
Fotivda
Tivozanib
Tivozanib
Sales:
$38.9 Million (2021)
$38.9 Million (2021)
| Patents | Expiration Date |
|---|---|
| US6821987 | April 26, 2023 |
| US7166722 | November 16, 2023 |
Dosage: Oral
Company: AVEO Pharmaceuticals
Ingredients: TIVOZANIB HYDROCHLORIDE
Treatment: Relapsed or Refractory Advanced Renal Cell Carcinoma (RCC)
Banzel
Rufinamide
Rufinamide
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US6740669 | May 14, 2023 |
Dosage: Oral
Company: Eisai Inc.
Ingredients: RUFINAMIDE
Treatment: Seizures Associated with Lennox-Gastaut syndrome
Nuzyra
Omadacycline
Omadacycline
Sales:
$38.8 million (2020)
$38.8 million (2020)
| Patents | Expiration Date |
|---|---|
| US7553828 | June 2, 2023 |
| US7326696 | September 24, 2023 |
| US8383610 | September 23, 2030 |
Dosage: Oral, Intravenous
Company: Paratek Pharmaceuticals
Ingredients: OMADACYCLINE TOSYLATE
Treatment: Community-acquired Bacterial Pneumonia and Acute Skin and skin structure infections
Halaven
Eribulin
Eribulin
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US6214865 | July 20, 2023 |
Dosage: Intravenous
Company: Eisai Inc.
Ingredients: ERIBULIN MESYLATE
Treatment: Breast Cancer and Liposarcoma
Dexilant
Dexlansoprazole
Dexlansoprazole
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US6664276 | July 30, 2023 |
Dosage: Oral
Company: Takeda
Ingredients: DEXLANSOPRAZOLE
Treatment: Gastroesophageal Reflux Disease
Onglyza
Saxagliptin
Saxagliptin
Sales:
$360 Million (2021)
$360 Million (2021)
| Patents | Expiration Date |
|---|---|
| USRE44186 | July 31, 2023 |
Dosage: Oral
Company: AstraZeneca
Ingredients: METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Treatment: Type 2 Diabetes
Vyvanse
Lisdexamfetamine
Lisdexamfetamine
Sales:
271.5 Billion JPY
271.5 Billion JPY
| Patents | Expiration Date |
|---|---|
| US7659253 | August 24, 2023 |
| US7655630 | August 24, 2023 |
| US7662787 | August 24, 2023 |
Dosage: Oral
Company: Shire (Takeda)
Ingredients: LISDEXAMFETAMINE DIMESYLATE
Treatment: Attention Deficit Hyperactivity Disorder (ADHD)
Lumigan
Bimatoprost
Bimatoprost
Sales:
$149 Million (2021)
$149 Million (2021)
| Patents | Expiration Date |
|---|---|
| US8038988 | August 25, 2023 |
| US7851504 | June 13, 2027 |
| US8629185 | July 15, 2031 |
Dosage: Eye Drops
Company: Allergan
Ingredients: BIMATOPROST
Treatment: High Pressure Inside the eye including Glaucoma
Vibativ
Telavancin
Telavancin
Sales:
$11.7 million (2021)
$11.7 million (2021)
| Patents | Expiration Date |
|---|---|
| US6635618 | September 11, 2023 |
| US7531623 | January 1, 2027 |
Dosage: Intravenous
Company: Theravance Biopharma
Ingredients: TELAVANCIN HYDROCHLORIDE
Treatment: MRSA or other Gram-positive infections
Lupron
Leuprorelin
Leuprorelin
Sales:
$783 Million (2021)
$783 Million (2021)
| Patents | Expiration Date |
|---|---|
| US8470359 | October 15, 2023 |
Dosage: Subcutaneous, Intramuscular
Company: AbbVie Inc
Ingredients: LEUPROLIDE ACETATE
Treatment: Prostate Cancer, Breast Cancer, Endometriosis, Uterine Fibroids
Feraheme
Ferric Carboxymaltose
Ferric Carboxymaltose
Sales:
$167.9 million (2020)
$167.9 million (2020)
| Patents | Expiration Date |
|---|---|
| US11123321 | October 20, 2023 |
| US9376505 | October 20, 2023 |
| US7612109 | February 5, 2024 |
Dosage: Intravenous
Company: AMAG Pharmaceuticals
Ingredients: FERRIC CARBOXYMALTOSE
Treatment: Iron-deficiency Anemia
Ozanex
Ozenoxacin
Ozenoxacin
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US6335447 | November 9, 2023 |
Dosage: Topical
Company: Cipher Pharmaceuticals
Ingredients: OZENOXACIN
Treatment: Impetigo
Stiolto® Respimat
Tiotropium/olodaterol
Tiotropium/olodaterol
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7491719 | November 10, 2023 |
| US7056916 | December 7, 2023 |
| US7220742 | May 12, 2025 |
| US7727984 | January 19, 2027 |
Dosage: Inhalation
Company: Boehringer Ingelheim Pharmaceuticals
Ingredients: OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
Treatment: Asthma
Otezla
Apremilast
Apremilast
Sales:
$2.2 billion (2020)
$2.2 billion (2020)
| Patents | Expiration Date |
|---|---|
| US7893101 | December 9, 2023 |
| US7427638 | February 16, 2028 |
Dosage: Oral
Company: Amgen Inc
Ingredients: APREMILAST
Treatment: Psoriasis and Psoriatic Arthritis
Rapivab
Peramivir
Peramivir
Sales:
$13.9 million (2020)
$13.9 million (2020)
| Patents | Expiration Date |
|---|---|
| US6562861 | December 16, 2023 |
Dosage: Intravenous
Company: BioCryst Pharmaceuticals
Ingredients: PERAMIVIR
Treatment: Influenza
VYNDAQEL
Tafamidis/Meglumine
Tafamidis/Meglumine
Sales:
$429 Million (2020)
$429 Million (2020)
| Patents | Expiration Date |
|---|---|
| US8168663 | December 19, 2023 |
| US7214695 | April 27, 2024 |
| US9770441 | August 31, 2035 |
Dosage: Oral
Company: Pfizer
Ingredients: TAFAMIDIS MEGLUMINE
Treatment: Transthyretin Amyloidosis
Coreg
Carvedilol
Carvedilol
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7268156 | December 27, 2023 |
Dosage: Oral
Company: GlaxoSmithKline
Ingredients: CARVEDILOL PHOSPHATE
Treatment: High Blood Pressure, Congestive Heart Failure (CHF), and Left Ventricular Dysfunction
Conclusion
As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.
With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.
Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team
